Original from: ORASURE

 

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2025.

 

“In Q3 we delivered $27.1 million of revenue. While some of our customers continue to experience elevated levels of uncertainty related to funding for public health programs and research, we remain confident in our opportunities to return to growth in 2026, driven by diversification in our customer base and contributions from planned launches of new products in both rapid diagnostics and sample management solutions,” said Carrie Eglinton Manner, President and CEO of OTI.

 

She continued, “OTI’s focus on decentralizing diagnostics and connecting people to care that is more accessible, convenient, private, and personalized is well-aligned with important long-term trends in the healthcare industry. We believe that this strategy and our capabilities position us for sustainable, long-term growth. Additionally, our strong balance sheet provides us with flexibility to navigate the current short-term turbulence while we advance our innovation roadmap and prepare for important new products that are expected to launch next year, including our Sherlock over-the-counter molecular self-test for Chlamydia and Gonorrhoeae and our Colli-Pee urine self-collection for sexually transmitted infections.”

 

Financial Highlights ($ in 000’s, except per share amounts)

 

 

· Total net revenues for the third quarter of 2025 decreased 32% to $27.1 million from $39.9 million in the third quarter of 2024.

 

· Core revenues (all revenues excluding COVID-19, Molecular Services, and Risk Assessment Testing revenues) of $27.0 million in the third quarter decreased 25% year-over-year. Diagnostics revenues in the third quarter decreased 34% year-over-year to $14.5 million, with the decline attributable to lower revenue from our HIV tests. Sample Management Solutions revenues in the third quarter decreased 20% year-over-year to $10.3 million, with the decline attributable to a large customer in the consumer genomics segment.

 

· GAAP gross margin was 43.5% in the third quarter of 2025 compared to 42.8% in the third quarter of 2024. Non-GAAP gross margin in the third quarter of 2025 was 44.2% compared to 43.3% in the third quarter of 20241.

 

· GAAP operating loss in the third quarter of 2025 was $16.1 million compared to operating loss of $6.0 million in the third quarter of 2024. Non-GAAP operating loss was $12.7 million in the third quarter of 2025 compared to non-GAAP operating loss of $2.7 million in the third quarter of 2024.

 

· Cash and cash equivalents were $216 million as of September 30, 2025.

 

· OTI deployed $5 million during the third quarter to repurchase approximately 1.5 million shares of our common stock.

 

Recent Business Developments

· Signed a definitive agreement to acquire BioMedomics. The transaction expands OTI’s diagnostic portfolio by adding SickleSCAN®, a rapid, point-of-need test for sickle cell disease that is currently sold outside the U.S. We believe OTI can significantly expand the reach and adoption of SickleSCAN® by leveraging our international sales channels and our existing relationships with national health programs.

 

· Extended our relationship with the Together Take Me Home program, a collaboration funded by the U.S. federal government that makes HIV self-tests available through the mail in order to reach at-risk populations.

 

· Selected by the ENDO1000 project to provide devices for collection and stabilization of a variety of samples including saliva, urine, stool, and vaginal swab. The ENDO1000 project is a U.K.-wide initiative aimed at accelerating discovery and advancing data-driven research into the diagnosis and personalized treatment of endometriosis.

 

· Appointed Steven K. Boyd to our Board of Directors as part of our ongoing refreshment efforts. Mr. Boyd is a seasoned investor who brings a valuable shareholder perspective and more than two decades of public markets experience across healthcare.

 

· Appointed Jack Kenny as Chair of our Board. Mr. Kenny has served as a director since September 2024. Mr. Kenny succeeds Mara Aspinall, who stepped down from the Board after more than eight years of service.

 

Financial Guidance

The Company is guiding to Q4 2025 Total revenues of $25 million to $28 million, which includes less than $100 thousand of COVID-19 testing revenues.

 

Source: ORASURE ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS